

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fang *et al.* Examiner: NYA.
Serial No: NYA Group Art Unit: NYA
Filing Date: June 28, 2004
Corresp. to: PCT/US02/40744
Int. Filing Date: December 18, 2002
Priority: December 28, 2001
Title: LUMINACIN ANALOGS AND USES THEREOF

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF EXPRESS MAILING

“Express Mail” mailing label number EV 314105083 US

Date of Deposit: June 28, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as "*Express Mail Post Office to Address*" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 *10/11/04*

Kathy Hart Gaylor
Signature

Signature 

Typed Name

Sir:

STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

An *original* Information Disclosure Statement; or

A *supplemental* Information Disclosure Statement.

The present Information Disclosure Statement is being filed:

Pursuant to 37 CFR § 1.97(b); no fee or certification is required:

Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);

Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;

Before the mailing of a first Office action on the merits; or

Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:

Certifies that *either*:

each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making

reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

- Includes herewith the fee set forth in § 1.17(p).
- Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:
 - Certifies that *either*:
 - each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

A copy of each cited reference not indicated with an asterisk is included;

Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

Does not contain non-English language citations;

Does contain non-English language citations, of which an English language translation of the Abstract for each is provided herein:

[] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



Nadège M. Lagneau, Ph.D.
Reg. No. 51,908

PATENT GROUP
CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Tel: (617) 248-5000
Fax: (617) 248-4000

Dated: June 28, 2004

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

App. No.

(VD 1207/US)

Not Yet Assigned

101500421

Applicant: Suzuki *et al*Filing Date:
June 28, 2004

Group:

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	JP 08268888	JP	Oct. 15, 1996		X
	JP 58116686	JP	Jul. 11, 1983		X
	JP 61293920	JP	Dec. 24, 1986		X
	JP 62294619	JP	Dec. 22, 1987		X
	JP 63048213	JP	Feb. 29, 1988		X
	JP 6322583	JP	Jan. 30, 1988		X
	WO 99/60000	PCT	Nov. 11, 1999		

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Naruse, et al., "Luminacins: A Family of Capillary Tube Formation Inhibitors from <i>Streptomyces</i> sp, I. Taxonomy, Fermentation, Isolation, Physico-chemical Properties and Structure Elucidation", <i>The Journal of Antibiotics</i> ; 53(6): 579-590, 2000.
	Sharma, et al., "USC15A, a non-kinase inhibitor of Src signal transduction", <i>Oncogene</i> , 20: 2068-2079, 2001.
	Tatsuta, et al., "The first total synthesis and establishment of absolute structure of luminacins C ₁ and C ₂ ", <i>Tetrahedron Letters</i> , 42: 7625-7628, 2001.
	Wakabayashi, et al., "Luminacins: A Family of Capillary Tube Formation Inhibitors from <i>Streptomyces</i> sp., II. Biological Activities", <i>The Journal of Antibiotics</i> , 53(6): 591-596, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.